Investing in the Future of Healthcare
The Sitala team are pioneers in the development of medicines designed to halt the progression of inflammatory and degenerative diseases. Our work is grounded in robust scientific research and clinical validation, which underpin the potential impact, safety and efficacy of our novel therapies.
By addressing unmet medical needs in both common and rare conditions, our pipeline is aligned with areas of significant patient need and substantial market opportunity. We are building on a strong track record of advancing development milestones in a timely manner, together with a bold and clear vision for meaningful progress in medicine.
Join us in transforming the future of healthcare.
OrbiMed seeks to invest globally in world-class healthcare companies to help drive innovation, address unmet medical needs, and improve patient outcomes.
Forbion is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies that transform people’s lives.
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.
British Business Bank is a government-owned development bank who work with a broad network of lenders, fund managers, and regional partners to deliver funding that helps smaller businesses grow and thrive.
Partner with us
Sitala is actively seeking in-licensing and partnering opportunities aligned with our mission to deliver next-generation anti-inflammatory medicines to the clinic. We welcome enquiries and proposals from potential partners who share our commitment to advancing new treatment options for patients with inflammatory diseases.